Tychos Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 3.60 M
as on 26-08-2024
- Paid Up Capital ₹ 3.60 M
as on 26-08-2024
- Company Age 21 Year, 7 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.14 Cr
as on 26-08-2024
- Satisfied Charges ₹ 3.70 Cr
as on 26-08-2024
- Revenue -12.35%
(FY 2023)
- Profit -29.35%
(FY 2023)
- Ebitda 3.10%
(FY 2023)
- Net Worth 10.83%
(FY 2023)
- Total Assets 19.08%
(FY 2023)
About Tychos Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.60 M and a paid-up capital of Rs 3.60 M.
The company currently has active open charges totaling ₹3.14 Cr. The company has closed loans amounting to ₹3.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
Maniyan Elangovan and Sunitha Nagarajan serve as directors at the Company.
- CIN/LLPIN
U51397TN2003PTC052144
- Company No.
052144
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Dec 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tychos Therapeutics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Maniyan Elangovan  | Managing Director | 15-Dec-2003 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sunitha Nagarajan | Director | 04-Mar-2013 | Current |
Financial Performance of Tychos Therapeutics.
Tychos Therapeutics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.35% decrease. The company also saw a substantial fall in profitability, with a 29.35% decrease in profit. The company's net worth Soared by an impressive increase of 10.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tychos Therapeutics?
Unlock access to Tychos Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Apr 2022 | ₹9.10 M | Open |
Hdfc Bank Limited Creation Date: 02 Mar 2016 | ₹2.23 Cr | Open |
Axis Bank Limited Creation Date: 07 Sep 2013 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Tychos Therapeutics?
Unlock and access historical data on people associated with Tychos Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tychos Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tychos Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
